scholarly journals Conquering rheumatoid arthritis. The latest breakthroughs and treatments: Thomas Lee. (Pp 250, $20.) Amherst, New York: Prometheus Books, 2001. ISBN 1-57392-886-0

2002 ◽  
Vol 61 (5) ◽  
pp. 477-b-477
Author(s):  
E M Veys
Keyword(s):  
Rheumatoid Arthritis ◽  
New York

scholarly journals Study of vertebral fracture and Scanographic Bone Attenuation Coefficient in rheumatoid arthritis and ankylosing spondylitis vs. controls

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Marine Fauny ◽  
Eliane Albuisson ◽  
Elodie Bauer ◽  
Julia Perrier-Cornet ◽  
Isabelle Chary-Valckenaere ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
New York ◽  
Ankylosing Spondylitis ◽  
Ct Scan ◽  
Attenuation Coefficient ◽  
Lumbar Vertebra ◽  
Bone Fragility ◽  
Control Group ◽  
T Score ◽  
Patients At Risk

Abstract The objective of this study is to identify the prevalence of vertebral fractures (VFs) and to measure the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1) based CT-scan, a biomarker of bone fragility in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and in a control group. This monocentric and retrospective study included patients with RA and AS, based on ACR/EULAR or New-York criteria, respectively. A control group was constituted. All of the patients received a CT-scan. VFs were determined via CT-scans according to the Genant classification, and the SBAC-L1 was measured in Hounsfield units (HU). SBAC-L1 ≤145 HU (fracture threshold) defined patients at risk of VFs. 244 patients were included (105 RA, 83 AS, 56 controls). Of the 4.365 vertebrae studied, 66 osteoporotic VFs were found in 36 patients: 18 (17.1%) RA, 13 (15.7%) AS and 5 (8.9%) controls. The mean SBAC-L1 was 142.2 (±48.4) HU for RA, 142.8 (±48.2) for AS, both of which were significantly lower than that of the control group (161.8 (±42.7) HU). Of the 36 patients with VFs and rheumatism, 28% had a T-score ≤−2.5 SD and 71.4% a SBAC-L1 ≤145 HU. A T-score ≤−2.5 SD and a SBAC-L1 ≤145 HU were associated with VF (OR = 3.07 (CI 95%: 1.07; 8.81), and 2.31 (CI 95%: 1.06; 5.06)), respectively. The SBAC-L1 was significantly lower in the RA and AS groups than in the control group. Furthermore, SBAC-L1 ≤145 HU was associated with a higher risk of VFs, with an odds ratio similar to that of a DXA.

scholarly journals Reducing Missed Opportunities for Influenza Vaccination in Patients with Rheumatoid Arthritis: Evaluation of a Multisystem Intervention

2018 ◽  
Vol 45 (9) ◽  
pp. 1220-1228 ◽  
Author(s):  
Rachel Broderick ◽  
Iazsmin Ventura ◽  
Sunoz Soroosh ◽  
Lourdes Franco ◽  
Jon T. Giles
Keyword(s):  
Rheumatoid Arthritis ◽  
New York ◽  
Influenza Vaccination ◽  
Office Visits ◽  
Negative Attitudes ◽  
Missed Opportunities ◽  
Multimodal Intervention ◽  
Black Patients ◽  
Before And After ◽  
Equivalent Efficacy

Objective.To assess a multimodal intervention for reducing missed opportunities for outpatient influenza vaccination in individuals with rheumatoid arthritis (RA).Methods.Patients with RA were enrolled from a single center and each rheumatology outpatient visit was tracked for missed opportunities for influenza vaccination, defined as a visit in which an unvaccinated patient without contraindications remained unvaccinated or lacked documentation of vaccine recommendation in the electronic medical record (EMR). Providers then received a multimodal intervention consisting of an education session, EMR alerts, and weekly provider-specific e-mail reminders. Missed opportunities before and after the intervention were compared, and the determinants of missed opportunities were analyzed.Results.A total of 228 patients with RA were enrolled (904 preintervention visits) and 197 returned for at least 1 postintervention visit (721 postintervention visits). The preintervention frequency of any missed opportunities for influenza vaccination was 47%. This was reduced to 23% postintervention (p < 0.001). Among those vaccinated, the relative hazard for influenza vaccination post- versus preintervention period was 1.24 (p = 0.038). Younger age, less frequent office visits, higher erythrocyte sedimentation rate, and negative attitudes about vaccines were each independently associated with missed opportunities preintervention. Postintervention, these factors were no longer associated with missed opportunities; however, the intervention was not as effective in non-Hispanic black patients, non-English speakers, those residing outside of the New York City metropolitan area, and those reporting prior adverse reactions to vaccines.Conclusion.Improved uptake of influenza vaccination in patients with RA is possible using a multimodal approach. Certain subgroups may need a more potent intervention for equivalent efficacy.

scholarly journals Special issue—before translational medicine: laboratory clinic relations lost in translation? Cortisone and the treatment of rheumatoid arthritis in Britain, 1950–1960

2019 ◽  
Vol 41 (4) ◽  
Author(s):  
Michael Worboys ◽  
Elizabeth Toon
Keyword(s):  
Rheumatoid Arthritis ◽  
New York ◽  
Clinical Practice ◽  
Translational Medicine ◽  
Bacterial Infections ◽  
Skin Diseases ◽  
Inflammatory Diseases ◽  
New York Times ◽  
Childhood Leukaemia ◽  
Therapeutic Uses

Abstract Cortisone, initially known as ‘compound E’ was the medical sensation of the late 1940s and early 1950s. As early as April 1949, only a week after Philip Hench and colleagues first described the potential of ‘compound E’ at a Mayo Clinic seminar, the New York Times reported the drug’s promise as a ‘modern miracle’ in the treatment of rheumatoid arthritis (RA). Given its high profile, it is unsurprising that historians of medicine have been attracted to study the innovation of cortisone. It arrived at the end of a decade of ‘therapeutic revolutions’, kicked off by penicillin transforming the treatment of bacterial infections and ending with hopes of a revolution in the treatment of non-infectious, chronic inflammatory diseases. Despite these studies of cortisone’s introduction, few historians have taken the story forward and considered how cortisone was adopted and adapted into clinical practice. This article tells the longer of how the drug and its derivatives were taken from research laboratories and integrated into clinical practice; what has in recent decades become known as translational medicine (TM). In exploring cortisone’s first decade in Britain, we focus specifically on its role in the treatment of RA. Our approach is always to consider cortisone’s use in the context of other treatments available to clinicians, and at local and national institutional settings. We do not discuss the many other therapeutic uses of cortisone, which ranged for topical applications for skin diseases to the management of cancers, especially childhood leukaemia, nor do we discuss its close analogue ACTH—AdenoCorticoTropic Hormone. We think there are lessons in our study for TM policies today.

Sign in / Sign up

Export Citation Format

Share Document